High-frequency microsatellite instability (MSI-H) results from deficiency in nucleotide mismatch repair. It contributes significantly to carcinogenesis in the human colorectal mucosa. Here we study 41 colorectal and three other HNPCC-related cancers with MSI-H to provide comprehensive information on the mechanisms of inactivation of the two major proteins involved, hMLH1 and hMSH2. Seventeen of the patients had family histories meeting the criteria for Bethesda grades 1, 2 or 3. Of these familial cases, 14 (83%) had early-onset disease, defined on the basis of diagnosis prior to the age of 50, but in three the disease was of late onset (450 years). A second subset of 20 patients had early onset disease without family history. The remaining seven patients were selected to allow comparisons with sporadic, late-onset disease, the molecular basis of which has been extensively reported elsewhere. We stratified the tumours initially on the basis of hMLH1 or hMSH2 protein deficiency, detected by immunohistochemistry, and then by analysis of germline and somatic mutation, mRNA transcription, loss of heterozygosity (LOH) at the hMLH1 and hMSH2 loci, and methylation status in two regions of the hMLH1 promoter. The functional significance of several of these changes in the MSI-H tumours was confirmed by comparisons with 16 tumours with low-frequency microsatellite instability and 56 tumours with stable microsatellites. As anticipated, patients with family histories usually showed germline mutation of hMSH2 or hMLH1. In many cases the residual normal allele was silenced in their tumours by loss of heterozygosity (LOH). The small subset of lateonset, sporadic cases confirmed the preponderance in this group of biallelic hMLH1 promoter methylation. In the early-onset, apparently sporadic subset there were 11 tumours with hMLH1 deficiency, five with hMSH2 deficiency and four with no detectable abnormality in expression of either protein. These showed a complex mixture of lesions, including germline and somatic mutations, promoter methylation, LOH, suppression of wild-type RNA by as yet undiscovered mechanisms, or no detectable abnormality in any of these parameters. Evidence is presented to indicate that methylation in proximal region of the hMLH1 promoter is a more reliable correlate of transcriptional silencing in colorectal cancers than methylation in upstream region. These observations have significant implications for management of patients with MSI-H tumours. Oncogene (2002) 21, 7585 -7592. doi:10.1038/sj.onc. 1205968
Keywords: microsatellite instability; promoter methylation; mismatch repair gene mutation; colorectal cancer; HNPCC High frequency microsatellite instability (MSI-H) is the phenotypic manifestation of mismatch repair defect. In colorectal carcinomas most MSI-H is associated with inactivation of either hMSH2 or hMLH1, genes that encode proteins involved early in the process of mismatch repair (MMR) (Peltomaki and Vasen, 1997) . Whilst germline MMR gene mutation is the major mechanism responsible for the mismatch repair deficiency in hereditary non-polyposis colorectal cancer (HNPCC) kindreds, the majority of sporadic late-onset MSI-H colorectal cancer were attributed to hMLH1 promoter hypermethylation (Kane et al., 1997; Herman et al., 1998; Cunningham et al., 1998; Kuismanen et al., 2000) . Cancers with MSI-H constitute a high proportion of those arising in the colon and rectum of younger patients, and whilst many of these have clear family histories of cancer, several do not. Relatively little is known of the molecular origins of the MMR deficiency in such apparently sporadic early-onset cancers, although we and others have shown that some arise on a background of germ-line mutation in hMSH-2 or hMLH1, despite the absence of family history (Liu et al., 1995; Chan et al., 1999a) . A comprehensive understanding of the mechanisms underlying MSI, in particular distinguishing between germline and somatic or epigenetic events, could significantly influence both the management of the patients and the level of surveillance required for their relatives. There is good reason to believe that the MSI-H phenotype requires bi-allelic ('two hit') inactivation of the responsible MMR gene. In practice, however, only a single inactivating event was identified in up to 65% of currently reported MSI-H colorectal tumours (Hemminki et al., 1994; Konishi et al., 1996; Tannergard et al., 1997; Leung et al., 1998; Chan et al., 1999b) . This may reflect the restricted number of inactivation mechanisms that were directly investigated. Moreover, there are technical limitations to the detection of mutations, be they germline or somatic, in the MMR genes. These large genes have no mutation hot spots and hence no simple strategy can detect all mutations. The simple detection of hMLH1 promoter hypermethylation also suffers from several drawbacks. Firstly, it does not distinguish between mono-allelic or bi-allelic inactivation in primary cancer tissue. Secondly, the specificity of promoter methylation and hence its functional significance varies according to the methods used and the CpG sites examined (Deng et al., 1999) . These limitations are particularly important for the group of sporadic early-onset colorectal cancer with MSI, where so far there is no comprehensive study addressing the relative contributions of germline, somatic and epigenetic events. Here we characterize the basis of MSI-H in a substantial number of MSI-H colorectal cancers, including familial, sporadic lateonset and sporadic early-onset cases, the latter group shows an exceptionally high incidence in Hong Kong (Yuen et al., 1997; Chan et al., 1999a) . For both hMSH2 and hMLH1 we sought to identify loss of protein expression, germline and somatic mutations, mRNA expression and LOH. Methylation was examined in various regions of the hMLH1 promoter. The data show that different mechanisms of MMR deficiency predominate in these three groups.
The results of immunohistochemical staining for hMSH2 and hMLH1, and the family or personal histories of cancer of 44 individuals with MSI-H tumours are shown in Table 1 and summarized in Figure 1 . In the majority of these tumours (38/44, 86%) one or other of the hMLH1 or hMSH2 proteins was undetectable. In contrast, both proteins were readily identified in a nuclear location in all of 16 tumours with low levels of microsatellite instability (MSI-L) and 56 tumours with stable microsatellites (MSS). When the MSI-H tumours were classified on the basis of age and family history into familial (satisfying Bethesda criteria 1, 2 or 3), sporadic earlyonset (aged 50 years or below at diagnosis) and sporadic late-onset (aged above 50 years) groups, all familial cases were found to have lost either hMSH2 (11/17, 65%) or hMLH1 (6/17, 35%). In the sporadic early-onset group, 55% (11/20) lost hMLH1 and 25% (5/20) lost hMSH2. In four cases (20%), however, nuclear staining for both proteins was retained. In the sporadic late-onset group, the majority (5/7, 71%) lost hMLH1 and none lost hMSH2.
The results of hMLH1 promoter methylation analysis are listed in Table 1 When bisulphite sequencing was used to identify methylation in a region more proximal to the transcription start site, covering bases 7178 to 7248 (referred to here as region 2), two distinct patterns emerged. DNA extracted from the tumour was either unmethylated in all eight CpG sites (hereafter referred to as the unmethylated pattern), or showed methylation close to or in excess of 50% of total DNA at all eight CpG sites (referred to as the methylated pattern) (Figure 2 ). Of the six tumours with normal expression of hMLH1 protein but with methylation in region 1 of the hMLH1 promoter, all showed an unmethylated pattern in region 2. Of the 12 tumours with loss of hMLH1 expression and methylated region 1, however, seven also showed the methylated pattern in region 2. Amongst the remaining five tumours, only two (L6, L20) failed to show clear evidence of bi-allelic inactivation of hMLH1 by means other than methylation (i.e. somatic or germline mutation together with LOH), and none failed to show at least one somatic or germline mutation ( Figure 2B ,C). In contrast, of the seven cases with region 2 methylation, five showed a predominance of methylated DNA in region 2 on bisulphite sequencing and absence of other germline or somatic inactivation events. Real time quantitative PCR of these cases demonstrated significantly lowered hMLH1 transcript when compared with 10 randomly selected MSS colorectal cancers (Figure 3 ). These results strongly support transcriptional silencing of hMLH1 in these cases by bi-allelic promoter methylation in region 2. Two further cases showed region 2 methylation and suppression of hMLH1 expression. In both, approximately 50% of region 2 DNA was methylated, suggesting monoallelic inactivation. One of these cases (L3) also had clear evidence of a germline mutation in hMLH1, whilst in the other (L22) a similar mutation might be inferred (although we did not detect it directly) since there was a family history satisfying Bethesda Criteria 2 and 3. Both these tumours, therefore, are likely to have arisen through germline mutation of one hMLH1 allele, and transcriptional silencing of the other through region 2 promoter methylation. Collectively, therefore, these results suggest that methylation in region 2 of the hMLH1 promoter is more specific for transcriptional silencing than in region 1. Table 1a and Figure 1 summarized the alterations of hMLH1 in colorectal cancers with hMLH1 protein loss. Overall, mono-or bi-allelic inactivation of hMLH1 was identified in 83% (18/22) of tumours that lacked hMLH1 protein expression. As expected from the published results of others, all but one of the five sporadic, late-onset tumours that lacked hMLH1 expression showed bi-allelic promoter methylation; in every case this was evident in region 2 as well as region 1 of the promoter.
Also concordant with previous reports were the results from the six familial cases. Most (5 of 6, 83%) had germline mutations. The 'second hit' leading to complete gene inactivation was identified in four of the tumours (three due to LOH, one with loss of wild type transcript of undetermined cause).
In contrast to these two groups, the sporadic, earlyonset patients showed remarkable plurality of mechanism for hMLH1 suppression. Three (L1, 2, 3) had germline mutations, two with LOH of the residual normal allele in their tumours, and region 2 promoter methylation in the third. Two had normal germline sequence but somatic mutations in their tumours (L4, 5). In one of these this was accompanied by LOH involving the residual normal allele, but in the other we did not identify a second lesion in DNA, although wild type RNA was lost. One showed LOH together with promoter methylation (L6), although this was found only in region 1. Only one of the 11 hMLH1 deficient tumours in the sporadic early-onset group showed biallelic methylation in region 2 (L7), a significantly lower incidence compared with the sporadic late-onset group, (P=0.01).
Most of the hMLH1 germline mutations identified in this study presented marked diagnostic challenge. The mutations, either in form of single nucleotide substitution that causes splicing defect (patients L17, L18, L1 and L19) or large genomic deletion (patients L2 and L20) (Chan et al., 2001) , all generate abnormal transcripts that are inherently unstable and mimic alternative splicing. The pathogenic significance of these mutations was revealed by examination of the microdissected tumour tissue, in which the wild type mRNA was absent, leaving only the truncated transcripts. Table 1b and Figure 1 summarized the mechanisms of hMSH2 protein loss. Germline hMSH2 mutation was detected in the majority of tumours deficient in hMSH2 expression (12/16, 75%), including 91% (10/ 11) of familial and 40% (2/5) of sporadic early-onset cases. The majority of mutations resulted in frameshifts or generation of truncated protein products. Interestingly, a 4-bp deletion involving nucleotides 1452-1455 of exon 9, reported by us previously (Chan et al., 1999a) and so far not identified in other ethnic groups, was found in five apparently unrelated patients (three familial and two early-onset sporadic) and constitutes BG2=individuals with two HNPCC-related cancers, including synchronous and metachronous colorectal cancers or associated extracolonic cancers (including endometrial, ovarian, gastric, hepatobiliary, small bowel cancer, transitional cell carcinomas of the renal pelvis or ureter, or § glioma); BG3=individuals with colorectal cancer and a first-degree relative with colorectal cancer and/or HNPCC-related extracolonic cancer and/or a colorectal adenoma (one of the cancers diagnosed at age younger than 45 years and the adenoma diagnosed at younger than 40 years); -=no personal or family history of cancer; y this patient had a first degree relative with colorectal cancer, and both were of late-onset. Blank denotes not studied Figure 1 Graphic presentation of the genetic/epigenetic events in relation to mismatch repair protein expression in 44 MSI-H colorectal and HNPCC-related tumours. The 41 high-level microsatellite instability (MSI-H) colorectal cancers in this study were identified in a systematic ongoing study of colorectal cancer in Hong Kong examined in the period 1991 to 1998. Three MSI-H cancers arising from other organs were also identified in the same study period from putative HNPCC families. Some of the colorectal cancer cases have been included in two previous reports of the incidence of MSI and germline MMR gene mutation in our early-onset population (Chan et al., 1999a; Ho et al., 2000) . Sixteen low-level microsatellite instability (MSI-L) and 56 microsatellite stable (MSS) colorectal cancers were also randomly selected from these series for comparison. These cases were either from patients who had undergone colectomy in our hospital, and thus there was frozen tumour tissue stored at 7708C available for study, or from patients who were referred to the Hereditary Gastrointestinal Cancer Registry for further work up because of young age at presentation or a positive family or personal history of cancer. The family history of cancer for all patients aged 50 years or below was ascertained using stringent criteria and method as described previously (Chan et al., 1999a; Ho et al., 2000) . For those aged above 50, a similar approach was used whenever possible, but otherwise the family history was obtained from the medical records. Cases were designated 'familial' if they had a family or personal history of cancer satisfying the Bethesda Criteria 1, 2 or 3 (Rodriguez-Bigas et al., 1997); otherwise, they were considered 'sporadic'. Because of the methods of case ascertainment and collection, the familial and early-onset MSI-H colorectal tumours are likely to be representative of tumours of this type in our community. The small number of late-onset MSI-H tumours, however, were drawn from a much larger population of sporadic tumours. Venous blood was taken, with informed consent, from the patients for extraction of DNA and RNA. This study was approved by the Ethics Committees of the University of Hong Kong and Queen Mary Hospital. DNA and/or RNA extraction from tumour, normal mucosa or blood leucocytes, and MSI analysis were performed as described (Chan et al., 1999a) . Sections were also microdissected in the analysis for LOH, bisulphite sequencing, quantitative RT -PCR and loss of wild type mRNA. Immunostaining for hMSH2 and hMLH1 was performed as described (Leung et al., 1999) . In vitro synthesized protein assays (IVSP) were used to screen for germline or somatic mutation of hMSH2 (Chan et al., 1999a) , and the site and nature of the underlying mutations were confirmed by direct DNA and cDNA sequencing. For cases showing altered hMSH2 protein by immunohistochemistry but without detectable truncated protein products by IVSP, direct sequencing of all exons of hMSH2 was performed. For the detection of hMLH1 mutation, direct cDNA sequencing of the whole gene was performed (Chan et al., 1999a) . In the majority of cases, frozen tumour tissue was available and mutation detection was performed in the tumour first. Confirmed tumour mutations were subsequently searched for in the germline. For those without frozen tumour/normal colorectal tissue, sequencing was performed in cDNA derived from the blood leukocytes. Missense mutations not previously reported to be pathogenic were further analysed by screening for allele frequency in the control healthy Chinese population using single-strand conformation polymorphism. For cases with detectable germline or somatic mutation, loss of heterozygosity (LOH) was determined by analysing the presence of the wild type allele by direct sequencing of DNA extracted from the microdissected tumour. For those without demonstrable mutation, or if the mutations were of large genomic deletions, LOH analysis was performed using microsatellites including D2S123, D3S1100, D3S1448, D3S3564 and D3S3593 as described by Wheeler et al. (1999) . RNA from microdissected tumour was used for the detection of loss of wild type mRNA in cases with mutation whenever frozen tumour samples were available. Data was cross-referenced with other data including promoter methylation and loss of heterozygosity (LOH) information of the respective gene. Only those cases without identifiable mechanism in the DNA level are highlighted in the results the most common germline hMSH2 mutation in this Hong Kong Chinese population. Two sporadic earlyonset tumours had somatic hMSH2 mutations only. In patient S3, though there was retention of heterozygosity at the DNA level, the wild type mRNA was not expressed in the cancer tissue. The genetic mechanisms underlying this loss of wild type mRNA, be they germline or somatic events, remained obscure. Overall, either one or two hit inactivation of hMSH2 was identified in 94% of cases with absence of hMSH2 protein expression. One prominent feature of these data is the ease with which the genetic basis of MSI-H tumours may be established, in the different patient groups, using immunohistochemistry for hMLH1 and hMLH2 as a primary screen. All of the tumours arising in patients with a family history (17/17) showed loss of one or other protein. This is also the case in 16 of 20 sporadic early onset tumours (80%) and five of seven sporadic late-onset cases (approximately 70%). In contrast, in tumours other than those with MSI-H, both proteins were invariably expressed. Further, these data show that virtually all patients with a family history satisfying not only Bethesda Criterion 1 (Amsterdam), but also the more relaxed Criteria 2 and 3, had detectable germline mutation in hMLH1 or hMSH2 (15 of 17, 83%).
In 21 of the 38 tumours showing loss of expression of hMLH1 or hMSH2 our methods accounted satisfactorily for suppression of both alleles. The commonest lesion in familial cases was LOH (6/17, 35%). In the small group of sporadic, late-onset tumours, as expected from the results of others, most showed bi-allelic promoter methylation in hMLH1 (5/ 6, 83%). The apparently sporadic early onset tumours, however, showed a complex mixture of germline and somatic mutation, LOH, promoter methylation or loss of wild type transcript for undetermined causes.
In three cases (L5, L20, S3) we showed unequivocal loss of wild type mRNA, but with convincing evidence for inactivation of only one of the alleles of the relevant MMR gene. It is not clear whether the failure to account for the loss of wild type mRNA in our cases is attributable to promoter mutation (Shin et al., 2002) Figure 2 Analysis of colorectal cancer for hMLH1 promoter methylation in region 2 using bisulphite DNA sequencing. CpG sites located in bases 7193 to 7231 relative to the transcription start site of hMLH1 were shown and underlined in (A) and (B). (A) a sporadic MSI-H colorectal cancer (patient L7) with loss of hMLH1 protein but have no detectable germline or somatic hMLH1 mutation. All CpG sites are methylated. Only small amount of unmethylated cytosines are present (likely from contaminating normal cells), indicating biallelic methylation. (B) and (C) a sporadic MSI-H colorectal cancer (patient L4) with hMLH1 promoter hypermethylation involving region 1 as detected by MS -PCR. All CpG sites are unmethylated in region 2 (B). Direct sequencing of hMLH1 in this tumour shows two hit inactivation in the DNA level, with delAG at the 3' end of exon 17 and loss of wild type allele (C). The mutations result in skipping of exon 17 and loss of the wild type mRNA. Genomic DNA was prepared from microdissected tumour tissue followed by bisulphite modification. Analysis for hMLH1 promoter methylation was performed using the following two methods: (1) Methylation-specific PCR using primers and methods similar to those described by Herman et al. (1998) . This examined methylation status of the CpG sites located in region 1. (2) Cases with methylation in region 1 and all cases with hMLH1 protein loss, were also subjected to bisulphite-sequencing procedure to determine the methylation status of 8 CpG sites located in region 2. The sequences of the primers were: F: TGTAAAACGACGGCCAGTTATTTTTGTTTTTATTGGTTGGATA, R: AATACCAATCAAATTTCTCAACTCT. The forward primer was tagged with M13. Bisulphite-modified DNA was amplified and the PCR products were sequenced using the DYEnamic ET Terminator Cycle Sequencing Kits (Amersham Pharmacia) with M13 as sequencing primer. The ratio of peak height of C to T at a CpG site indicates the ratio of methylated to unmethylated cytosine or to other events that adversely affect the transcription, processing or stability of mRNA.
In the course of this study, we compared the association of methylation in two regions of the hMLH1 promoter with suppression of the protein product. One of the major problems in the analysis of hMLH1 promoter hypermethylation derives from the fact that, of the several CpG rich regions within the promoter, methylation in some may correlate better than others with transcriptional silencing and loss of the protein. Deng et al. (1999) examined different regions of the hMLH1 promoter, and found that methylation of CpG sites in region 2 correlated best with MSI and hMLH1 protein loss in colorectal cancer cell lines. Moreover, this group has shown by functional assay that this proximal region of the hMLH1 promoter is capable of driving transcription, and methylation of this region is more important than the upstream regions in inhibiting transcription (Deng et al., 2001) . Subsequently, others have demonstrated methylation in the upstream regions both in normal mucosa and a small number of colorectal cancers without protein loss or MSI phenotype (Deng et al., 2002) . Our present study using primary cancer tissue, with exhaustive and systematic analysis of hMLH1, provides additional evidence for the relative significance of methylation in these two regions. Using bisulphite sequencing performed on microdissected cancer tissue, we have proven that biallelic methylation in region 2 is invariably associated with transcriptional silencing of the gene, loss of the protein, and absence of DNA mutation. Methylation of region 2 in monoallelic form may also act as the second hit event. In contrast, the functional significance of methylation in region 1, especially when assessed by MSP in which only a few CpG sites are examined and the extent of methylated alleles are not known, should be interpreted with caution. It can occur in tumours with no hMLH1 protein loss, and in tumours that already harbour twohit inactivation of hMLH1. Our data thus support the functional significance of hMLH1 promoter methylation involving region 2 in primary colorectal cancer tissue and the use of bisulphite sequencing to assess methylation in this region.
The management of patients with MSI-H colorectal cancer can be greatly influenced by information on its genetic basis. This is particularly true when the tumours arise in young subjects, and when family history is unclear. We show here that a combination of germline and somatic mutations, LOH, monoallelic hMLH1 promoter hypermethylation and loss of wild type mRNA accounts for the loss of hMSH2 or hMLH1 proteins in a substantial proportion of these sporadic early-onset tumours. In contrast, bi-allelic promoter methylation, the predominant cause of MSI-H in late-onset cancers, is rare in the early-onset group. However, the data presented here also show that in a small proportion of sporadic early-onset tumours where deficiency of mismatch repair protein expression was clearly established, no satisfactory explanation for suppression of the relevant mismatch repair gene was demonstrated. Moreover, alterations in these two genes are rarely seen in sporadic MSI-H tumours when the corresponding proteins are normally expressed. It remains to be seen whether germline or somatic events affecting other MMR genes, in particular hMSH6, hPMS1 or hPMS2, are responsible for the mismatch repair deficiency in these cases. Me+ MSI CRC, MSI-H colorectal cancers with hypermethylation involving regions 1 and 2 of hMLH1 promoter and without detectable mutation in the gene. Line inside box, the median; upper and lower limits of box, hinges -75th and 25th percentiles, respectively; vertical bars above and below the box, the upper and lower quartiles, respectively. *The difference in hMLH1 level between the two groups is statistically significant (Mann-Whitney U test, P50.001). 2 -3 mg of total RNA extracted from microdissected tumour tissue was reverse transcribed into first-strand cDNAs. Real-time quantitative RT -PCR was performed using LightCycler -FastStart DNA Master SYBR Green I (Roche Diagnostics Ltd.) according to the manufacturer's protocol. Primers for the detection of hMLH1 were forward primer 5'-AAGAAGATCTGGATATTGTATGTG-3' and reverse primer 5'-CCTAACATCAGCTACTGTCTCTCC-3'. The human b-actin was used for standardization of the initial RNA content of a sample. The primers for human b-actin were forward primer 5'-ACTCTTCCAGCCTTCCTTCC-3' and reverse primer 5'-CGTCATACTCCTGCTTGCTG-3'. For hMLH1, 6 pmol of each primer, 5 mM of MgCl 2 and an annealing temperature of 628C were used. For b-actin, 3 pmol of each primer, 3 mM of MgCl 2 and an annealing temperature of 608C were used. The PCR was run at 958C for 10 min for antibody inactivation, followed by 45 to 55 cycles of amplification at 958C for 15 s, specific annealing temperature for 5 s and 728C for 12 s, with a temperature slope of 208C per s. Real-time PCR monitoring was achieved by measuring the SYBR Green I signal at 828C and 868C after the extension period for hMLH1 and b-actin respectively. Melting curves were analysed in each run to ensure that the products were homogeneous. To quantitate the amount of specific mRNA in the samples, a standard curve was generated for each run using serial dilution of a reference cDNA generated from a lymphoblastoid cell line of a normal individual. This standard curve was used to calculate the concentration of the template copies in the unknown samples. All the experiments were performed in duplicate and the result for individual sample was expressed as the mean level of hMLH1/b-actin relative to the reference lymphoblastoid cell line
In conclusion, our study has revealed different pathways of carcinogenesis in MSI-H colorectal tumours, related to age of onset of the disease and the presence or absence of family history. The observations impact on management, since relatives of patients with germline mutations require stringent prophylactic screening, whilst those of patients with two-hit somatic inactivations or bi-allelic promoter methylation without mutation should be relieved of the psychological burden of suspected cancer susceptibility.
